← Back to All Filings

Greenwich LifeSciences CEO/CFO Buys $21k in GLSI Stock

Low SignificanceNovember 4, 2025 at 7:03:37 AM EST

Greenwich LifeSciences, Inc.

$GLSI4CIK: 0001799788

Subscribe to track GLSI

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Greenwich LifeSciences CEO/CFO Buys $21k in GLSI Stock

Company: Greenwich LifeSciences, Inc. (GLSI) Form: 4 | Filed: 2025-11-04 Significance: Low

Insider: Patel Snehal Title: CEO and CFO | Relationship: Director, Officer, 10% Owner

Transaction: • Type: Purchase • Shares: 2,300 • Price: $9.26 • Value: $21,298 • Owned After: 5,572,902

Key Insight: A small open-market purchase by the CEO, who already holds a substantial position of over 40% of the company's outstanding shares.

Market Context: The transaction represents a negligible percentage of the company's market cap and shares outstanding, making it a routine filing.

View Full Filing

This is PUBLIC SEC data for educational purposes. Not investment advice.

Comprehensive Analysis

SEC Filing Analysis: Greenwich LifeSciences, Inc. (GLSI)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: The CEO and CFO, Snehal Patel, made a small open-market purchase, slightly increasing an already massive ownership stake.
  • Market Impact: The transaction is immaterial relative to the company's market capitalization and public float, suggesting a neutral market impact.

Company Information

FieldValue
CompanyGreenwich LifeSciences, Inc.
Ticker SymbolGLSI
CIK0001799788
IndustryPHARMACEUTICAL PREPARATIONS [2834]

Insider Information

FieldValue
NamePatel Snehal
CIK0001806920
Title/PositionCEO and CFO
RelationshipDirector, Officer, 10% Owner

Transaction Details

FieldValue
Form Type4
Transaction Date2025-10-31
Transaction CodeP (Open market or private purchase)
Security TypeCommon Stock
Shares Involved2,300
Price Per Share$9.26
Total Value$21,298
Shares Owned After5,572,902
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$21,298
% of Market Cap0.019%
Shares Transacted2,300
% of Shares Outstanding0.017%
Post-Transaction Ownership5,572,902 shares (40.89% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: With a market cap of $110 million, this $21,298 transaction is financially insignificant for the company.
  • Ownership Concentration: The insider already holds a controlling stake of over 40% of all outstanding shares. This purchase is a minor addition to that substantial position.
  • Transaction Significance: The purchase represents less than 0.02% of both market cap and shares outstanding, falling well below any threshold for material significance.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The transaction is too small to be considered a meaningful signal of insider confidence or to have any market-moving impact.

Volume & Sentiment

  • Expected Volume Impact: Negligible. The trade size is too small to affect trading volume.
  • Sentiment Indicator: Neutral. While an insider buy is technically a positive sign, its minuscule size renders it neutral in this context.
Topics:#SECFiling#InsiderTrading#GLSI#Form4#InsiderBuy#GreenwichLifeSciences#StockMarket#Investing

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.